Several other hedge funds have also recently bought and sold shares of NVO. Finally, Advisory Services Network LLC purchased a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $127,000. The firm owned 43,164 shares of the company’s stock after buying an additional 14,999 shares during the period. Renaissance Technologies LLC raised its position in shares of Novo Nordisk A/S by 17.7% in the first quarter. Mycio Wealth Partners LLC now owns 20,280 shares of the company’s stock worth $695,000 after buying an additional 155 shares in the last quarter. Global X Management Co. Parallel Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 120.3% in the first quarter. Novo Nordisk said that, despite an anticipated slowdown in US sales next year, linked in part to lower rebates for diabetes treatments, it sees second half sales, on a local currency basis, to rise between 1% and 3%, a slightly firmer guidance than the group provided earlier this year. Neuberger Berman Group LLC now owns 45,660 shares worth $1,958,000.
The biggest institutional shareholders in Novo Nordisk A/S include Renaissance Technologies Corp which owns 16 million shares in the company valued at $562.51 million. HSBC upgraded the shares of NVO in report on Wednesday, August 31 to “Hold” rating.
Novo Nordisk’s share price had risen by almost 6% in three-and-a-half hours of trading on Wednesday after the results were announced, reaching 275.70 kroner. The firm owned 5,639 shares of the company’s stock after selling 450 shares during the period. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $48.58. The company has a market capitalization of $102.70 billion, a PE ratio of 17.20 and a beta of 0.63. The stock’s 50 day moving average price is $42.86 and its 200-day moving average price is $38.45.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of worldwide trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/08/5000-shares-in-novo-nordisk-as-nysenvo-acquired-by-trust-co-of-oklahoma-updated-updated-updated.html. Citigroup downgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Monday, October 31 to “Neutral” rating. Research Firm Zacks boosted Novo Nordisk A/S from a “hold” recommendation to a “buy” recommendation and fixed a $49.00 PT for the company in a study note published on Wed, Jun 21st. Finally, TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd.
Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. This method of adaptation features a fast and a slow moving average so that the composite moving average swiftly responds to price changes and holds the average value until the next bar’s close.
Diabetes and obesity care sales were up 8% in local currencies for the quarter, at 23.77 billion kroner, with Victoza (liraglutide) earning the company 5.78 billion kroner, 15% more, and NovoRapid’s (insulin aspart) revenue up by 3% at 5.09 billion kroner.
The company believes that the tough trading conditions in the USA, such as lower prices, generic products and rising competition and poor economic state in a number of worldwide markets would keep the level of growth under control. It operates in the business of developing novel therapies for the management of CNS disorders segment. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.